XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.26.1

Note 10 - Share-based Compensation | 6 Months Ended
--- | ---
Mar. 31, 2026
Notes to Financial Statements |
Share-Based Payment Arrangement [Text Block] | Note 10 – Share-based Compensation We allocate share-based compensation expense to general and administrative expense and research and development expense based on the award holder’s employment function. For the three and six months ended March 31, 2026 and 2025, we recorded share-based compensation expenses as follows:
|  | Three Months Ended |  |  | Six Months Ended |
|  | March 31, |  |  | March 31, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
General and administrative |  | $ | 311,852 |  |  | $ | 1,618,958 |  |  | $ | 905,058 |  |  | $ | 3,623,674 |
Research and development |  |  | 90,860 |  |  |  | 604,885 |  |  |  | 255,259 |  |  |  | 1,284,323 |
Discontinued operations |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (10,049 | )
Share-based compensation |  | $ | 402,712 |  |  | $ | 2,223,843 |  |  | $ | 1,160,317 |  |  | $ | 4,897,948 |
We have issued share-based awards to employees and non-executive directors under the Company’s approved equity plans. Upon the exercise of share-based awards, new shares are issued from authorized common stock. Equity Plans In June 2022, the Company’s board of directors adopted the Company’s 2022 Employment Inducement Equity Incentive Plan (the “Inducement Plan”). The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules. The Inducement Plan is used exclusively for the issuance of equity awards to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual’s entry into employment with the Company. The Company reserved 400,000 shares of common stock under the Inducement Plan and as of March 31, 2026, 400,000 shares are available for issuance under the Inducement Plan. In March 2018, the Company’s stockholders approved the Company's 2018 Equity Incentive Plan (as amended, the “2018 Plan”). On March 12, 2026, the Company’s stockholders approved an increase in the number of shares that may be issued under the 2018 Plan to 5.85 million. As of March 31, 2026, 3,914,259 shares remain available for issuance under the 2018 Plan. In July 2017, the Company’s stockholders approved the Company's 2017 Equity Incentive Plan (the “2017 Plan”). A total of 470,000 shares are authorized for issuance under the 2017 Plan. As of March 31, 2026, 21,512 shares remain available for issuance under the 2017 Plan. The 2017 Plan replaced the Company's 2008 Stock Incentive Plan (the “2008 Plan”), and no further awards will be made under the 2008 Plan. Stock Options Each option grants the holder the right to purchase from us one share of our common stock at a specified price, which is generally the closing price per share of our common stock on the date the option is issued. Options generally vest on a pro-rata basis on each anniversary of the issuance date within three years of the date the option is issued. Options may be exercised after they have vested and prior to the specified expiry date provided applicable exercise conditions are met, if any. The expiry date can be for periods of up to ten years from the date the option is issued. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions established at that time. The Company accounts for forfeitures as they occur and does not estimate forfeitures as of the option grant date. The Company recognized a reduction in share-based compensation expense for stock options forfeited during the period of $0 and $0.1 million during the three months ended March 31, 2026 and 2025, respectively. The following table outlines the weighted average assumptions for options granted during the three and six months ended March 31, 2026 and 2025:
|  | Three Months Ended |  |  | Six Months Ended |
|  | March 31, |  |  | March 31, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
Weighted Average Assumptions: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected volatility |  |  | — |  |  |  | 115.5 | % |  |  | 116.6 | % |  |  | 110.2 | %
Expected dividend yield |  |  | — |  |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %
Risk-free interest rate |  |  | — |  |  |  | 4.1 | % |  |  | 3.8 | % |  |  | 3.6 | %
Expected term (in years) |  |  | — |  |  |  | 6.0 |  |  |  | 6.0 |  |  |  | 6.0 |
Fair value of options granted |  | $ | — |  |  | $ | 3.88 |  |  | $ | 2.20 |  |  | $ | 6.28 |
During the three and six months ended March 31, 2026 and 2025, the Company used historical volatility of our common stock over a period equal to the expected life of the options to estimate their fair value. The dividend yield assumption is based on the Company’s recent history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term. The following table summarizes the stock options outstanding and exercisable at March 31, 2026:
|  |  |  |  |  | Weighted Average |  |  |  |  |
|  |  |  |  |  |  |  |  |  | Remaining |  |  | Aggregate |
|  | Number of |  |  | Exercise Price |  |  | Contractual Term |  |  | Intrinsic |
|  | Shares |  |  | Per Share |  |  | (years) |  |  | Value |
Outstanding at September 30, 2025 |  |  | 1,911,020 |  |  | $ | 42.18 |  |  |  |  |  |  |  |  |
Granted |  |  | 350,700 |  |  | $ | 2.55 |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  | $ | — |  |  |  |  |  |  |  |  |
Forfeited and expired |  |  | (171,742 | ) |  | $ | 40.32 |  |  |  |  |  |  |  |  |
Outstanding at March 31, 2026 |  |  | 2,089,978 |  |  | $ | 35.68 |  |  |  | 5.81 |  |  | $ | — |
Exercisable at March 31, 2026 |  |  | 1,436,000 |  |  | $ | 49.29 |  |  |  | 4.30 |  |  | $ | — |
The aggregate intrinsic values in the table above are before income taxes and represent the number of in-the-money options outstanding or exercisable multiplied by the closing price per share of the Company’s common stock on the last trading day of the quarter ended March 31, 2026 of $2.21, less the respective weighted average exercise price per share at period end. As of March 31, 2026, the Company had unrecognized compensation expense of approximately $1.9 million related to unvested stock options. This expense is expected to be recognized over a weighted average period of 2.1 years. Stock Appreciation Rights In connection with the closing of our acquisition of Aspen Park Pharmaceuticals, Inc. on October 31, 2016 (the “APP Acquisition”), the Company issued stock appreciation rights based on 5,000 and 14,000 shares of the Company’s common stock to an employee and an outside director, respectively, that vested on October 31, 2018. The stock appreciation rights have a ten-year term and an exercise price per share of $9.50, which was the closing price per share of the Company’s common stock as quoted on Nasdaq on the trading day immediately preceding the date of the completion of the APP Acquisition. Upon exercise, the stock appreciation rights will be settled in common stock issued under the 2017 Plan. As of March 31, 2026, vested stock appreciation rights based on 5,000 shares of common stock remain outstanding.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration